U.S. Markets close in 5 hrs 29 mins

Lpath Initiates Dosing of iSONEP in First of Two Proof-of-Concept Trials

SAN DIEGO, CA--(Marketwire -09/29/11)- Lpath, Inc. (OTC.BB: LPTN.OB - News), the industry leader in lipidomics-based antibody therapeutics, has initiated dosing in its PEDigree clinical trial where iSONEP™ is being investigated as a treatment for retinal pigment epithelium detachment ("RPE detachment" or "PED"). Lpath entered into an agreement with Pfizer (NYSE: PFE - News) in 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP.

In this human proof-of-concept trial, Lpath plans to dose 32 subjects -- 16 at a lower dose and 16 at a higher dose -- that have PED secondary to wet age-related macular degeneration (wet AMD) or polypoidal choroidal vasculopathy (PCV).

PED is a potentially serious condition that is often part of the pathology of wet AMD and PCV, yet no drug has yet been approved to treat PED. Even though patients with PED were excluded from the Lucentis® pivotal trials, this drug is often used to treat such patients, but with incomplete success. As such, the prognosis for those suffering from PED continues to be poor.

Subjects in the PEDigree trial will receive up to three monthly intravitreal injections of iSONEP. The primary safety endpoint is the tolerability of consecutive monthly injections, and the primary efficacy endpoint is the percentage of subjects that experience complete flattening of their PED.

In Lpath's Phase 1 trial, where subjects with wet AMD received only one injection, iSONEP met its primary endpoint of being well tolerated in all 15 patients. It also succeeded in meeting a key secondary endpoint in that a positive biological effect -- with a single dose -- was observed in most patients, almost all of whom had failed to respond to Lucentis and/or Avastin® treatment.

One of the distinct benefits in Phase 1 was the resolution (complete flattening) of PEDs in two out of the two subjects that presented with PED. One of these patients received no further treatment with the "standard of care" (Lucentis or Avastin) during the entire 12-month monitoring period following the iSONEP injection. The other was not re-treated until day 105. These extended times to re-treatment suggest that any benefit derived from iSONEP is durable, a particularly important attribute in this market.

Lpath hypothesizes that such distinctive benefits are due to iSONEP's powerful anti-inflammatory and anti-fibrotic mechanisms of action. In various animal models of disease, iSONEP was shown to substantially reduce inflammation in the eye (Campochiaro et al., Journal of Cellular Physiology, October 2008) and significantly mitigate ocular fibrosis (Grant et al., Experimental Eye Research, August 2008).

The potential market for a drug that fully resolves PED is significant: it is estimated more than 500,000 people currently have PED, and with reasonable assumptions, the attainable market size is estimated to be more than $1.0 billion globally. These figures are expected to grow significantly as the "baby boomers" fill up the ranks of the 65+ age group.

Lpath plans to soon begin another iSONEP trial, a double-blind, 160-subject human-proof-of-concept trial to study the efficacy and safety of iSONEP in the broader wet-AMD patient population.

Glenn Stoller, MD, head of Lpath's ocular division, commented: "iSONEP is a first-in-class drug that has distinguished itself with promising animal data and, more recently, human data. A growing independent body of literature suggests that iSONEP's distinctive anti-inflammatory, anti-angiogenic and anti-fibrotic mechanisms could prevent both the early and the late stages of retinal damage, including the damage that often results when a PED fails to flatten over time."

Scott Pancoast, Lpath's president and chief executive officer, added: "Because anti-VEGF agents like Lucentis and Avastin have demonstrated lackluster results in the treatment of PED patients, there is a significant unmet medical need. Both subjects presenting with PED in our Phase 1 trial experienced a complete flattening of the PED. While that is a very small population, we are hopeful that we will see similar results in larger groups of patients as we continue our clinical development program."

Lucentis® and Avastin® are registered trademarks of Roche.

About Lpath
San Diego-based Lpath, a therapeutic antibody company, is the category leader in lipidomics-based antibody therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath's ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company has developed three drug candidates, one of which (iSONEP™ for wet AMD) has initiated mid-stage clinical trials and another of which (ASONEP™ for cancer) will soon begin mid-stage clinical trials. The third candidate is a pre-clinical anti-LPA antibody, which has shown efficacy in animal models of pain, fibrosis, and traumatic brain injury. Lpath entered into an agreement with Pfizer (NYSE: PFE - News) in 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP. For more information, visit www.Lpath.com.

About Forward-Looking Statements
The Company cautions you that the statements included in this press release that are not a description of historical facts are forward-looking statements. These include statements regarding: the eventual commercial viability of the Company's drug programs, and the eventual revenues that the Company would attain if the drug eventually gets approved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company's business, including, without limitation: the results of any future clinical trials for iSONEP may not be favorable and the Company may never receive regulatory approval for iSONEP; and the Company may not be able to secure the funds necessary to support its clinical trial and product development plans. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

  • Coronavirus fears spook stocks: Here's how to keep a cool head and protect your 401(k)
    Business
    USA TODAY

    Coronavirus fears spook stocks: Here's how to keep a cool head and protect your 401(k)

    Sign up here Here are four moves experts say could help protect your investments during volatile periods, such as the bumpy stretch caused by the coronavirus: 401(k): Coronavirus fears shouldn't stop you from investing in stocks Monitoring markets: Dow jumps 300 points as investors assess economic fallout from virus 1. Review your investments Pay attention to where you're invested and which companies are most likely to be affected, portfolio managers say. Daniel Milan, managing partner at Southfield, Michigan-based Cornerstone Financial Services, says the effects from the virus outbreak on the stock market will be short-lived and has cautioned his clients to not let fear drive their investme...

  • Wait for these signals to buy coronavirus-battered stocks, says BNY Mellon strategist
    Business
    MarketWatch

    Wait for these signals to buy coronavirus-battered stocks, says BNY Mellon strategist

    Some believe the next big fall in equities will come when we see a cluster of U.S. cases, which may partly explain why that popular past time of buying stocks on any dip seems less popular lately. Citigroup strategists are advising against buying equities right now, on the view that if a Federal Reserve lifeline is coming, it may not happen right away. Gov. Warsh argues for immediate, globally coordinated rate cut Our call of the day comes from BNY Mellon's chief strategist Alicia Levine, who has advice for those wanting to know when to buy beaten-down (and down) stocks.

  • Something 'dangerous' is happening beneath the surface of the market selloff
    Business
    Yahoo Finance

    Something 'dangerous' is happening beneath the surface of the market selloff

    So every time stocks went up, bonds tailed off and vice-versa,” Academy Securities' Peter Tchir said on Yahoo Finance's The Final Round. All of a sudden, that behavior changed a little bit into the close yesterday. And making it even more dangerous to me, you saw oil fall off into the close.

  • Business
    TheStreet.com

    Jim Cramer on Coronavirus: What It Means for Markets, Federal Reserve and Microsoft

    Jim Cramer has some thoughts on the markets, the Federal Reserve and Microsoft as coronavirus fears shake Wall Street. Stock futures declined sharply Thursday, putting Wall Street on pace for its worst week since the global financial crisis in 2008, as coronavirus infections accelerated and health officials confirmed that a California man contracted the disease despite having no travel links or contacts with those afflicted by the virus. The company warned investors that it will fall short of previously issued fiscal third-quarter sales guidance of between $10.75 billion and $11.15 billion for its "more personal computing" segment, which includes Windows OEM and Surface.

  • 3M's making protective masks on three continents, but it's not enough
    News
    American City Business Journals

    3M's making protective masks on three continents, but it's not enough

    The Star Tribune has an update on 3M's mask-making efforts; the Maplewood-based company has boosted production in China — the epicenter of the Covid-19 outbreak, where tens of thousands of people have gotten sick — as well as at factories elsewhere in Asia, Europe, Latin America and the United States. That's been the case now for nearly a month; 3M (NYSE: MMM) CEO Mike Roman said in January that the company was "going 24/7" in producing the masks in factories across the globe. But the spread of the virus — and the worries that it could get even worse — have meant that the company, along with other mask producers, is still playing catch-up.

  • Virgin Galactic misses expectations in the fourth quarter
    Business
    Yahoo Finance Video

    Virgin Galactic misses expectations in the fourth quarter

    Virgin Galactic CEO George T. Whitesides joins the On The Move panel to discuss why the space company missed analyst expectations during the fourth quarter and what investors should look for moving forward.

  • Business
    Barrons.com

    Fear Has Overtaken This Market. How to Use It to Turn a Profit.

    In anticipation, the stock market has experienced some of its most dramatic losses in two years. The profound rotation away from risk assets into Treasury bonds earlier this week into government debt and away from stocks should be considered as a warning shot across the equity market's bow. Early next week, the Institute for Supply Management will release its February report on U.S. economic activity, and similar reports will be released that measure economic activity all over the world.

  • Trump talks about the stock market, and gets 1 out of 3 points right
    Business
    MarketWatch

    Trump talks about the stock market, and gets 1 out of 3 points right

    Stock markets do this all the time. Since Trump was elected president in November 2016, the Dow has risen from around 18,000 to around 27,000. Trump went on an extended riff blaming the market's fall on Tuesday's Democratic presidential debate.

  • 'Stuck in no man’s land': A working mom details being stuck with her sick child's student loan bill
    Business
    Yahoo Finance

    'Stuck in no man’s land': A working mom details being stuck with her sick child's student loan bill

    Unforeseen medical expenses piled up for a son diagnosed with leukemia, and her family is stuck without any of the repayment options offered to regular student loan borrowers. Consequently, she said she was feeling “stuck in no man's land,” and the financial pain was intensifying. The Trump administration reportedly considered ways to help people like Natalie with their student debt, specifically with their Parent PLUS loans, given the relative age of the borrowing group.

  • Tesla Sinks on Weak China Registrations Before Brunt of Virus
    Business
    Bloomberg

    Tesla Sinks on Weak China Registrations Before Brunt of Virus

    Tesla Inc. shares fell after China registration data indicated a significant sequential slowdown in demand before the electric-car maker started feeling the brunt of any impact from the coronavirus. Registrations of new Tesla cars plunged 46% to 3,563 in January from December, according to state-backed China Automotive Information Net, which gathers industry data based on insurance purchases. Of the January registrations, 2,605 were for cars built in China.

  • 3 “Strong Buy” Stocks Holding Steady Amid Coronavirus Concerns
    Business
    TipRanks

    3 “Strong Buy” Stocks Holding Steady Amid Coronavirus Concerns

    Coronavirus fears have weighed heavily on the market, and investors are seeking refuge. While the situation in China is reportedly improving, health officials warn the spike in new cases throughout the rest of the world underscores the risk of a global pandemic. Against this backdrop, Wall Street pros remind investors not to panic and rush to a sell-off, pointing out that a select group of tickers still represent compelling opportunities.

  • 3 Stocks Warren Buffett and Leon Cooperman Agree On
    Business
    GuruFocus.com

    3 Stocks Warren Buffett and Leon Cooperman Agree On

    According to the Aggregated Portfolio, a Premium feature of GuruFocus, three stocks billionaire investors Warren Buffett (Trades, Portfolio) and Leon Cooperman (Trades, Portfolio) both own in their investment vehicles, Berkshire Hathaway Inc. NYSE:BRK.A)(NYSE:BRK.B) and the Omega Advisors family office, are Wells Fargo & Co. (NYSE:WFC), United Airlines Holdings Inc. NASDAQ:UAL) and Amazon.com Inc.

  • Dow Jones Tumbles On U.S. Virus First, Microsoft Coronavirus Warning
    Business
    Investor's Business Daily

    Dow Jones Tumbles On U.S. Virus First, Microsoft Coronavirus Warning

    Earlier, Wednesday's stock market rally attempt fizzled as the Covid-19 virus continued to spread around the globe. Meanwhile, Carvana, Square, Teladoc Health, Anaplan and Etsy offered notable earnings reports overnight. Gilead Sciences announced trials for its antiviral Remdesivir to treat the coronavirus.

  • Chesapeake Energy’s ‘very low’ stock price prompts reverse split plans
    Business
    MarketWatch

    Chesapeake Energy’s ‘very low’ stock price prompts reverse split plans

    Shares of Chesapeake Energy Corp. tumbled to another record low Wednesday, after the oil and natural gas production company said it was planning for a reverse stock split and that the commodities pricing environment has “further deteriorated” in recent weeks. The company also reported before the market opened a fourth-quarter loss that was narrower than expected, but revenue that fell more than forecast, as production increased while average prices for oil, natural gas and natural gas liquids (NGL) production all fell. Chief Executive Doug Lawler tried to assuage investors by saying on the post-earnings conference call with analysts that given improvements to margins and moves made to strengthen the balance sheet, “the previous going concern language will not be present” in the 2019 annual report, but the stock continued to sell off.

  • Protective Mask Maker Soars As Orders Surge Amid Worsening Coronavirus
    Business
    Investor's Business Daily

    Protective Mask Maker Soars As Orders Surge Amid Worsening Coronavirus

    Alpha Pro Tech announced a spike in face mask orders amid the spiraling coronavirus outbreak, a day after disclosing earnings for the fourth quarter. APT stock soared, also boosting Lakeland Industries. APT said Thursday it has booked about $14.1 million face mask orders since Jan. 27.

  • Square earnings net stock an upgrade as analyst sees huge market for Cash App
    Business
    MarketWatch

    Square earnings net stock an upgrade as analyst sees huge market for Cash App

    Square Inc. shares are up 5% in Thursday trading after the company topped earnings expectations, shrugged off coronavirus concerns, and gave new information about the growth of its popular Cash App. The increasing use of various Cash App features like investing and card purchases is fueling excitement around Square's (SQ) business, helping net the payments platform stock an upgrade from Canaccord Genuity's Joseph Vafi after the report. Cash App began as a peer-to-peer payments platform, but the company has been adding new features to the ecosystem, including the ability to conduct equity trading in the app.

  • Bristol-Myers Squibb Company Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
    Business
    Simply Wall St.

    Bristol-Myers Squibb Company Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

    Bristol-Myers Squibb Company (NYSE:BMY) shares fell 4.8% to US$62.04 in the week since its latest yearly results. It was an okay result overall, with revenues coming in at US$26b, roughly what analysts had been expecting. This is an important time for investors, as they can track a company's performance in its report, look at what top analysts are forecasting for next year, and see if there has been any change to expectations for the business.

  • There is not a 'better time,' for Disney to name Bob Chapek as CEO: Analyst
    Business
    Yahoo Finance Video

    There is not a 'better time,' for Disney to name Bob Chapek as CEO: Analyst

    Shares of Disney are under pressure Wednesday as Bob Chapek begins his first day as the CEO of Disney. Tuna Amobi, CFRA Analyst, discusses with Yahoo Finance's On The Move.

  • Top Gold Stocks for March 2020
    Business
    Investopedia

    Top Gold Stocks for March 2020

    Gold has long been regarded as a safe haven in times of market turmoil. Many investors have gained exposure to the gold industry by buying stocks of companies engaged in the exploration and mining of the precious metal. Some of the biggest names in the gold industry include mining companies such as Newcrest Mining Ltd. (NCM), Wheaton Precious Metals Corp.

  • Suze Orman: The 60-40 portfolio 'is dead'
    Business
    Yahoo Money

    Suze Orman: The 60-40 portfolio 'is dead'

    Financial advisors have long stood by the golden rule of having a portfolio of 60% stocks and 40% bonds, but Suze Orman says the rule no longer applies. Actually, 60-40 is dead,” Orman, founder of the Suze Orman Financial Group, said on Yahoo Finance's On the Move. It should probably be 75-25 stocks, believe it or not, stocks, if you also have enough cash to get you by.

  • Is Now The Time To Look At Buying Southwest Airlines Co. (NYSE:LUV)?
    Business
    Simply Wall St.

    Is Now The Time To Look At Buying Southwest Airlines Co. (NYSE:LUV)?

    Today we're going to take a look at the well-established Southwest Airlines Co. (NYSE:LUV). The company's stock saw significant share price movement during recent months on the NYSE, rising to highs of US$58.54 and falling to the lows of US$48.90. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price.

  • Coronavirus fears prompt action for Louisville businesses
    Business
    American City Business Journals

    Coronavirus fears prompt action for Louisville businesses

    Several Louisville businesses and organizations are considering their responses as fears of a COVID-19 coronavirus outbreak in the U.S. grow. "Out of an abundance of caution, UPS has put in place health and hygiene measures that are in line with suggested World Health Organization measures," Mike Mangeot, public relations manager for United Parcel Service Inc., said in a statement to Business First. "However, given the scale and ongoing challenges with China resuming normal business activities, there will be some impact in our International segment this quarter." He also noted that people receiving packages are not at risk of contracting the virus.

  • Southern Research collaborating to develop coronavirus vaccine
    Business
    American City Business Journals

    Southern Research collaborating to develop coronavirus vaccine

    Birmingham-based Southern Research has entered into a strategic collaboration with New York-based clinical-stage biopharmaceutical company Tonix Pharmaceuticals to support the development of a vaccine against the new coronavirus disease, COVID-19. According to Southern Research, the new research collaboration will develop and test a potential horsepox vaccine that expresses protein from the virus that causes COVID, a SARS-CoV-2, to protect against the disease. “We look forward to this collaboration to advance a potential COVID-19 vaccine,” said Scott Goebel, a senior scientist in Southern Research's Drug Development division and principal investigator of the project.

  • Business
    Bloomberg

    A Bailout Won’t Help China’s Tesla Wannabe, NIO

    New York-listed NIO Inc., a self-described pioneer in China's premium electric vehicle market and rival to Elon Musk's company, said Tuesday that it has made a tentative agreement with the municipal government of Hefei in Anhui province for funding support. The company will move its China headquarters there from Shanghai and says it plans to raise more than 10 billion yuan ($1.43 billion) in light of the partnership.

  • This is the No. 1 mistake investors are making now — here’s how to avoid it
    Business
    MarketWatch

    This is the No. 1 mistake investors are making now — here’s how to avoid it

    The stock market is under pressure. Investors are reacting — badly. The No. 1 mistake investors are making now in the wake of coronavirus has to do with their artificial construct of the true nature of the stock market.